UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients-Reference-Cited by-同舟云学术

UGT1A1 genotype-guided dosing of irinotecan: A prospective safety and cost analysis in poor metaboliser patients

Published:2022-02 Issue: Volume:162 Page:148-157
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Hulshof Emma C.^ORCID,de With Mirjam^ORCID,de Man Femke M.,Creemers Geert-Jan^ORCID,Deiman Birgit A.L.M.,Swen Jesse J.,Houterman Saskia^ORCID,Koolen Stijn L.W.,Bins Sander^ORCID,Thijs Anna M.J.,Laven Marjan M.J.,Hövels Anke M.,Luelmo Saskia A.C.^ORCID,Houtsma Danny,Shulman Katerina,McLeod Howard L.^ORCID,van Schaik Ron H.N.,Guchelaar Henk-Jan,Mathijssen Ron H.J.^ORCID,Gelderblom Hans,Deenen Maarten J.^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Individualization of irinotecan treatment: a review of pharmacokinetics, pharmacodynamics, and pharmacogenetics;de Man;Clin Pharmacokinet,2018

2. Pharmacogenomics knowledge for personalized medicine;Whirl-Carrillo;Clin Pharmacol Ther,2012

3. Irinogenetics: how many stars are there in the sky?;Mathijssen;J Clin Oncol,2009

4. Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study;Crona;Pharmacogenomics J,2016

5. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics;Innocenti;J Clin Oncol,2009

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. First-line palliative systemic therapy alternated with oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy for unresectable colorectal peritoneal metastases: A single-arm phase II trial (CRC-PIPAC-II);European Journal of Surgical Oncology;2024-09

2. Irinotecan dosing and pharmacogenomics: a comprehensive exploration based on UGT1A1 variants and emerging insights;Journal of Chemotherapy;2024-05-06

3. Model‐Based Prediction of Irinotecan‐Induced Grade 4 Neutropenia in Cancer Patients: Influence of Incorporating Germline Genetic Factors in the Model;Clinical Pharmacology & Therapeutics;2024-02-12

4. Real Life Data and Outcome of FOLFIRINOX Use in Metastatic Pancreatic Cancer Patients in General Hospitals in the Netherlands;Journal of Gastrointestinal Cancer;2024-02-06

5. Intraperitoneal irinotecan with concomitant FOLFOX and bevacizumab for patients with unresectable colorectal peritoneal metastases: protocol of the multicentre, open-label, phase II, INTERACT-II trial;BMJ Open;2024-01